Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Blackstone, CD&R among PE firms exploring bids for Magnum - report

(Sharecast News) - Shares of Magnum Ice Cream Company surged on Friday following a report that Blackstone and CD&R are among private equity ‌firms in the early stages of exploring bids for the company. According to Reuters, citing two sources familiar with the matter, the firms are monitoring Magnum's share price before deciding whether to make a move for the company, which was recently spun out of Unilever.

Unilever retains a 19.9% stake in ​Magnum and plans to exit within five years.

Reuters said deliberations are at an early stage and both ​PE firms are waiting for Magnum to report summer sales before making a decision. ‌Magnum makes ⁠a large share of its revenue during that period.

Sources told Reuters that other private equity firms are also interested.

Magnum Ice Cream Company declined to comment on the report.

At 1212 BST, Magnum shares were up 17% at 1,314.55p.

Share this article

Related Sharecast Articles

RBC Capital cuts Rathbones price target after regulatory update
(Sharecast News) - RBC Capital Markets cut its price target on Rathbones on Thursday to 1,950p from 2,400p following the company's surprise regulatory update earlier in the week, which it said will likely complicate and lengthen the group's turnaround story.
Berenberg downgrades Anglo American to 'hold'
(Sharecast News) - Berenberg downgraded Anglo American on Thursday to 'hold' from 'buy' as it took a look at metals and mining stocks, saying it was taking a "breather" following a strong share price performance.
FCA to take no action as it closes Drax probe
(Sharecast News) - Drax said on Thursday that the Financial Conduct Authority had closed its investigation into the company with no action to be taken.
Syncona reports broadly stable net asset value
(Sharecast News) - Syncona reported broadly stable net asset value for the year ended 31 March on Thursday, as gains at Beacon Therapeutics offset weakness elsewhere in its life sciences portfolio, while the healthcare investor reiterated plans to return at least £250m to shareholders.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.